Global PD-1 and PD-L1 Immunotherapy Market Insights and Forecast to 2031

Report ID: 1639294 | Published Date: Oct 2024 | No. of Page: 113 | Base Year: 2023 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 PD-1 inhibitor
        1.2.3 PD-L1 inhibitor
    1.3 Market by Application
        1.3.1 Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Solid Tumors
        1.3.3 Blood-related Tumors
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global PD-1 and PD-L1 Immunotherapy Market Perspective (2017-2028)
    2.2 PD-1 and PD-L1 Immunotherapy Growth Trends by Region
        2.2.1 PD-1 and PD-L1 Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 PD-1 and PD-L1 Immunotherapy Historic Market Size by Region (2017-2022)
        2.2.3 PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Region (2023-2028)
    2.3 PD-1 and PD-L1 Immunotherapy Market Dynamics
        2.3.1 PD-1 and PD-L1 Immunotherapy Industry Trends
        2.3.2 PD-1 and PD-L1 Immunotherapy Market Drivers
        2.3.3 PD-1 and PD-L1 Immunotherapy Market Challenges
        2.3.4 PD-1 and PD-L1 Immunotherapy Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top PD-1 and PD-L1 Immunotherapy Players by Revenue
        3.1.1 Global Top PD-1 and PD-L1 Immunotherapy Players by Revenue (2017-2022)
        3.1.2 Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Players (2017-2022)
    3.2 Global PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by PD-1 and PD-L1 Immunotherapy Revenue
    3.4 Global PD-1 and PD-L1 Immunotherapy Market Concentration Ratio
        3.4.1 Global PD-1 and PD-L1 Immunotherapy Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Immunotherapy Revenue in 2021
    3.5 PD-1 and PD-L1 Immunotherapy Key Players Head office and Area Served
    3.6 Key Players PD-1 and PD-L1 Immunotherapy Product Solution and Service
    3.7 Date of Enter into PD-1 and PD-L1 Immunotherapy Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 PD-1 and PD-L1 Immunotherapy Breakdown Data by Type
    4.1 Global PD-1 and PD-L1 Immunotherapy Historic Market Size by Type (2017-2022)
    4.2 Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Type (2023-2028)
5 PD-1 and PD-L1 Immunotherapy Breakdown Data by Application
    5.1 Global PD-1 and PD-L1 Immunotherapy Historic Market Size by Application (2017-2022)
    5.2 Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America PD-1 and PD-L1 Immunotherapy Market Size (2017-2028)
    6.2 North America PD-1 and PD-L1 Immunotherapy Market Size by Type
        6.2.1 North America PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022)
        6.2.2 North America PD-1 and PD-L1 Immunotherapy Market Size by Type (2023-2028)
        6.2.3 North America PD-1 and PD-L1 Immunotherapy Market Share by Type (2017-2028)
    6.3 North America PD-1 and PD-L1 Immunotherapy Market Size by Application
        6.3.1 North America PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022)
        6.3.2 North America PD-1 and PD-L1 Immunotherapy Market Size by Application (2023-2028)
        6.3.3 North America PD-1 and PD-L1 Immunotherapy Market Share by Application (2017-2028)
    6.4 North America PD-1 and PD-L1 Immunotherapy Market Size by Country
        6.4.1 North America PD-1 and PD-L1 Immunotherapy Market Size by Country (2017-2022)
        6.4.2 North America PD-1 and PD-L1 Immunotherapy Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe PD-1 and PD-L1 Immunotherapy Market Size (2017-2028)
    7.2 Europe PD-1 and PD-L1 Immunotherapy Market Size by Type
        7.2.1 Europe PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022)
        7.2.2 Europe PD-1 and PD-L1 Immunotherapy Market Size by Type (2023-2028)
        7.2.3 Europe PD-1 and PD-L1 Immunotherapy Market Share by Type (2017-2028)
    7.3 Europe PD-1 and PD-L1 Immunotherapy Market Size by Application
        7.3.1 Europe PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022)
        7.3.2 Europe PD-1 and PD-L1 Immunotherapy Market Size by Application (2023-2028)
        7.3.3 Europe PD-1 and PD-L1 Immunotherapy Market Share by Application (2017-2028)
    7.4 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country
        7.4.1 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country (2017-2022)
        7.4.2 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size (2017-2028)
    8.2 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Type
        8.2.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Share by Type (2017-2028)
    8.3 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Application
        8.3.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Share by Application (2017-2028)
    8.4 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Region
        8.4.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America PD-1 and PD-L1 Immunotherapy Market Size (2017-2028)
    9.2 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Type
        9.2.1 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022)
        9.2.2 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Type (2023-2028)
        9.2.3 Latin America PD-1 and PD-L1 Immunotherapy Market Share by Type (2017-2028)
    9.3 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Application
        9.3.1 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022)
        9.3.2 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Application (2023-2028)
        9.3.3 Latin America PD-1 and PD-L1 Immunotherapy Market Share by Application (2017-2028)
    9.4 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country
        9.4.1 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country (2017-2022)
        9.4.2 Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size (2017-2028)
    10.2 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Type
        10.2.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Share by Type (2017-2028)
    10.3 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Application
        10.3.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Share by Application (2017-2028)
    10.4 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Country
        10.4.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 AstraZeneca
        11.1.1 AstraZeneca Company Details
        11.1.2 AstraZeneca Business Overview
        11.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Introduction
        11.1.4 AstraZeneca Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.1.5 AstraZeneca Recent Developments
    11.2 Bristol-Myers Squibb
        11.2.1 Bristol-Myers Squibb Company Details
        11.2.2 Bristol-Myers Squibb Business Overview
        11.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Introduction
        11.2.4 Bristol-Myers Squibb Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.2.5 Bristol-Myers Squibb Recent Developments
    11.3 F. Hoffmann-La Roche
        11.3.1 F. Hoffmann-La Roche Company Details
        11.3.2 F. Hoffmann-La Roche Business Overview
        11.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Introduction
        11.3.4 F. Hoffmann-La Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.3.5 F. Hoffmann-La Roche Recent Developments
    11.4 Merck
        11.4.1 Merck Company Details
        11.4.2 Merck Business Overview
        11.4.3 Merck PD-1 and PD-L1 Immunotherapy Introduction
        11.4.4 Merck Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.4.5 Merck Recent Developments
    11.5 Pfizer
        11.5.1 Pfizer Company Details
        11.5.2 Pfizer Business Overview
        11.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Introduction
        11.5.4 Pfizer Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.5.5 Pfizer Recent Developments
    11.6 Roche
        11.6.1 Roche Company Details
        11.6.2 Roche Business Overview
        11.6.3 Roche PD-1 and PD-L1 Immunotherapy Introduction
        11.6.4 Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.6.5 Roche Recent Developments
    11.7 Novartis
        11.7.1 Novartis Company Details
        11.7.2 Novartis Business Overview
        11.7.3 Novartis PD-1 and PD-L1 Immunotherapy Introduction
        11.7.4 Novartis Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.7.5 Novartis Recent Developments
    11.8 Jiangsu HengRui Medicine
        11.8.1 Jiangsu HengRui Medicine Company Details
        11.8.2 Jiangsu HengRui Medicine Business Overview
        11.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Introduction
        11.8.4 Jiangsu HengRui Medicine Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.8.5 Jiangsu HengRui Medicine Recent Developments
    11.9 Innovent
        11.9.1 Innovent Company Details
        11.9.2 Innovent Business Overview
        11.9.3 Innovent PD-1 and PD-L1 Immunotherapy Introduction
        11.9.4 Innovent Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.9.5 Innovent Recent Developments
    11.10 Eli Lilly
        11.10.1 Eli Lilly Company Details
        11.10.2 Eli Lilly Business Overview
        11.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Introduction
        11.10.4 Eli Lilly Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.10.5 Eli Lilly Recent Developments
    11.11 GlaxoSmithKline
        11.11.1 GlaxoSmithKline Company Details
        11.11.2 GlaxoSmithKline Business Overview
        11.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Introduction
        11.11.4 GlaxoSmithKline Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
        11.11.5 GlaxoSmithKline Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer

List of Tables
    Table 1. Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of PD-1 inhibitor
    Table 3. Key Players of PD-L1 inhibitor
    Table 4. Global PD-1 and PD-L1 Immunotherapy Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 5. Global PD-1 and PD-L1 Immunotherapy Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global PD-1 and PD-L1 Immunotherapy Market Size by Region (2017-2022) & (US$ Million)
    Table 7. Global PD-1 and PD-L1 Immunotherapy Market Share by Region (2017-2022)
    Table 8. Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 9. Global PD-1 and PD-L1 Immunotherapy Market Share by Region (2023-2028)
    Table 10. PD-1 and PD-L1 Immunotherapy Market Trends
    Table 11. PD-1 and PD-L1 Immunotherapy Market Drivers
    Table 12. PD-1 and PD-L1 Immunotherapy Market Challenges
    Table 13. PD-1 and PD-L1 Immunotherapy Market Restraints
    Table 14. Global PD-1 and PD-L1 Immunotherapy Revenue by Players (2017-2022) & (US$ Million)
    Table 15. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Players (2017-2022)
    Table 16. Global Top PD-1 and PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Immunotherapy as of 2021)
    Table 17. Ranking of Global Top PD-1 and PD-L1 Immunotherapy Companies by Revenue (US$ Million) in 2021
    Table 18. Global 5 Largest Players Market Share by PD-1 and PD-L1 Immunotherapy Revenue (CR5 and HHI) & (2017-2022)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players PD-1 and PD-L1 Immunotherapy Product Solution and Service
    Table 21. Date of Enter into PD-1 and PD-L1 Immunotherapy Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
    Table 24. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Type (2017-2022)
    Table 25. Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 26. Global PD-1 and PD-L1 Immunotherapy Revenue Market Share by Type (2023-2028)
    Table 27. Global PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
    Table 28. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Application (2017-2022)
    Table 29. Global PD-1 and PD-L1 Immunotherapy Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 30. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Application (2023-2028)
    Table 31. North America PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
    Table 32. North America PD-1 and PD-L1 Immunotherapy Market Size by Type (2023-2028) & (US$ Million)
    Table 33. North America PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
    Table 34. North America PD-1 and PD-L1 Immunotherapy Market Size by Application (2023-2028) & (US$ Million)
    Table 35. North America PD-1 and PD-L1 Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
    Table 36. North America PD-1 and PD-L1 Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
    Table 37. Europe PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
    Table 38. Europe PD-1 and PD-L1 Immunotherapy Market Size by Type (2023-2028) & (US$ Million)
    Table 39. Europe PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
    Table 40. Europe PD-1 and PD-L1 Immunotherapy Market Size by Application (2023-2028) & (US$ Million)
    Table 41. Europe PD-1 and PD-L1 Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
    Table 42. Europe PD-1 and PD-L1 Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
    Table 43. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
    Table 44. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size by Type (2023-2028) & (US$ Million)
    Table 45. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
    Table 46. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size by Application (2023-2028) & (US$ Million)
    Table 47. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size by Region (2017-2022) & (US$ Million)
    Table 48. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size by Region (2023-2028) & (US$ Million)
    Table 49. Latin America PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
    Table 50. Latin America PD-1 and PD-L1 Immunotherapy Market Size by Type (2023-2028) & (US$ Million)
    Table 51. Latin America PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
    Table 52. Latin America PD-1 and PD-L1 Immunotherapy Market Size by Application (2023-2028) & (US$ Million)
    Table 53. Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
    Table 54. Latin America PD-1 and PD-L1 Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
    Table 55. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
    Table 56. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size by Type (2023-2028) & (US$ Million)
    Table 57. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
    Table 58. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size by Application (2023-2028) & (US$ Million)
    Table 59. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
    Table 60. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
    Table 61. AstraZeneca Company Details
    Table 62. AstraZeneca Business Overview
    Table 63. AstraZeneca PD-1 and PD-L1 Immunotherapy Product
    Table 64. AstraZeneca Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 65. AstraZeneca Recent Developments
    Table 66. Bristol-Myers Squibb Company Details
    Table 67. Bristol-Myers Squibb Business Overview
    Table 68. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product
    Table 69. Bristol-Myers Squibb Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 70. Bristol-Myers Squibb Recent Developments
    Table 71. F. Hoffmann-La Roche Company Details
    Table 72. F. Hoffmann-La Roche Business Overview
    Table 73. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product
    Table 74. F. Hoffmann-La Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 75. F. Hoffmann-La Roche Recent Developments
    Table 76. Merck Company Details
    Table 77. Merck Business Overview
    Table 78. Merck PD-1 and PD-L1 Immunotherapy Product
    Table 79. Merck Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 80. Merck Recent Developments
    Table 81. Pfizer Company Details
    Table 82. Pfizer Business Overview
    Table 83. Pfizer PD-1 and PD-L1 Immunotherapy Product
    Table 84. Pfizer Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 85. Pfizer Recent Developments
    Table 86. Roche Company Details
    Table 87. Roche Business Overview
    Table 88. Roche PD-1 and PD-L1 Immunotherapy Product
    Table 89. Roche Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 90. Roche Recent Developments
    Table 91. Novartis Company Details
    Table 92. Novartis Business Overview
    Table 93. Novartis PD-1 and PD-L1 Immunotherapy Product
    Table 94. Novartis Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 95. Novartis Recent Developments
    Table 96. Jiangsu HengRui Medicine Company Details
    Table 97. Jiangsu HengRui Medicine Business Overview
    Table 98. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product
    Table 99. Jiangsu HengRui Medicine Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 100. Jiangsu HengRui Medicine Recent Developments
    Table 101. Innovent Company Details
    Table 102. Innovent Business Overview
    Table 103. Innovent PD-1 and PD-L1 Immunotherapy Product
    Table 104. Innovent Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 105. Innovent Recent Developments
    Table 106. Eli Lilly Company Details
    Table 107. Eli Lilly Business Overview
    Table 108. Eli Lilly PD-1 and PD-L1 Immunotherapy Product
    Table 109. Eli Lilly Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 110. Eli Lilly Recent Developments
    Table 111. GlaxoSmithKline Company Details
    Table 112. GlaxoSmithKline Business Overview
    Table 113. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product
    Table 114. GlaxoSmithKline Revenue in PD-1 and PD-L1 Immunotherapy Business (2017-2022) & (US$ Million)
    Table 115. GlaxoSmithKline Recent Developments
    Table 116. Research Programs/Design for This Report
    Table 117. Key Data Information from Secondary Sources
    Table 118. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global PD-1 and PD-L1 Immunotherapy Market Share by Type: 2021 VS 2028
    Figure 2. PD-1 inhibitor Features
    Figure 3. PD-L1 inhibitor Features
    Figure 4. Global PD-1 and PD-L1 Immunotherapy Market Share by Application: 2021 VS 2028
    Figure 5. Solid Tumors Case Studies
    Figure 6. Blood-related Tumors Case Studies
    Figure 7. PD-1 and PD-L1 Immunotherapy Report Years Considered
    Figure 8. Global PD-1 and PD-L1 Immunotherapy Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 9. Global PD-1 and PD-L1 Immunotherapy Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 10. Global PD-1 and PD-L1 Immunotherapy Market Share by Region: 2021 VS 2028
    Figure 11. Global PD-1 and PD-L1 Immunotherapy Market Share by Players in 2021
    Figure 12. Global Top PD-1 and PD-L1 Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Immunotherapy as of 2021)
    Figure 13. The Top 10 and 5 Players Market Share by PD-1 and PD-L1 Immunotherapy Revenue in 2021
    Figure 14. North America PD-1 and PD-L1 Immunotherapy Market Size YoY (2017-2028) & (US$ Million)
    Figure 15. North America PD-1 and PD-L1 Immunotherapy Market Size Market Share by Type (2017-2028)
    Figure 16. North America PD-1 and PD-L1 Immunotherapy Market Size Market Share by Application (2017-2028)
    Figure 17. North America PD-1 and PD-L1 Immunotherapy Market Size Share by Country (2017-2028)
    Figure 18. United States PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Canada PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe PD-1 and PD-L1 Immunotherapy Market Size YoY (2017-2028) & (US$ Million)
    Figure 21. Europe PD-1 and PD-L1 Immunotherapy Market Size Market Share by Type (2017-2028)
    Figure 22. Europe PD-1 and PD-L1 Immunotherapy Market Size Market Share by Application (2017-2028)
    Figure 23. Europe PD-1 and PD-L1 Immunotherapy Market Size Share by Country (2017-2028)
    Figure 24. Germany PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. France PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. U.K. PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Italy PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Russia PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Nordic Countries PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size YoY (2017-2028) & (US$ Million)
    Figure 31. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size Market Share by Type (2017-2028)
    Figure 32. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size Market Share by Application (2017-2028)
    Figure 33. Asia Pacific PD-1 and PD-L1 Immunotherapy Market Size Share by Region (2017-2028)
    Figure 34. China PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Japan PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. South Korea PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. India PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Australia PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 40. Latin America PD-1 and PD-L1 Immunotherapy Market Size YoY (2017-2028) & (US$ Million)
    Figure 41. Latin America PD-1 and PD-L1 Immunotherapy Market Size Market Share by Type (2017-2028)
    Figure 42. Latin America PD-1 and PD-L1 Immunotherapy Market Size Market Share by Application (2017-2028)
    Figure 43. Latin America PD-1 and PD-L1 Immunotherapy Market Size Share by Country (2017-2028)
    Figure 44. Mexico PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Brazil PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size YoY (2017-2028) & (US$ Million)
    Figure 47. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size Market Share by Type (2017-2028)
    Figure 48. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size Market Share by Application (2017-2028)
    Figure 49. Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size Share by Country (2017-2028)
    Figure 50. Turkey PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 51. Saudi Arabia PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 52. UAE PD-1 and PD-L1 Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 53. AstraZeneca Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 54. Bristol-Myers Squibb Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 55. F. Hoffmann-La Roche Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 56. Merck Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 57. Pfizer Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 58. Roche Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 59. Novartis Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 60. Jiangsu HengRui Medicine Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 61. Innovent Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 62. Eli Lilly Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 63. GlaxoSmithKline Revenue Growth Rate in PD-1 and PD-L1 Immunotherapy Business (2017-2022)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AstraZeneca
Bristol-Myers Squibb
F. Hoffmann-La Roche
Merck
Pfizer
Roche
Novartis
Jiangsu HengRui Medicine
Innovent
Eli Lilly
GlaxoSmithKline
Frequently Asked Questions
PD-1 and PD-L1 Immunotherapy report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
PD-1 and PD-L1 Immunotherapy report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
PD-1 and PD-L1 Immunotherapy report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

GLP-1R Agonist

GLP-1R Agonist market is segmented by players, region (country), by Type and by Application. Play ... Read More

Incretin Mimetics

Incretin Mimetics market is segmented by players, region (country), by Type and by Application. P ... Read More